Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Academy in NOLA: retina durability, gene therapies, and TED data lead clinical highlights

11 October 2026 · By · Wire by Fusion42

Published

11 October 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at glance.eyesoneyecare.com →

◆ Verified

Fusion42 · 11 October 2026 · Fusion42 review

The 2026 American Academy of Ophthalmology meeting highlighted advances in retina durability including positive Phase 3 data from Kodiak Sciences for wet AMD and diabetic retinopathy treatments, along with progress in gene therapies. AI integration into clinical workflows and targeted ocular surface treatments were also major themes.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You must explore retina therapies with longer durability and gene-based mechanisms now proving clinical effectiveness. Advances in AI for clinic workflows mean you need to embed these tools early to stay competitive.

◆ Coverage

1 source · 11 Oct 2026

◆ Related on Wire

◆ Topics

Medtechophthalmologyretinagene-therapyclinical-trialsAI-integration